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Abstract
Background: Radiographic image guidance is routinely used for patient positioning in radiotherapy. All radiographic
guidance techniques can give a significant radiation dose to the patient. The dose from diagnostic imaging is usually
managed by using effective dose minimization. In contrast, image-guided radiotherapy adds the imaging dose to an
already high level of therapeutic radiation which cannot be easily managed using effective dose. The purpose of this
work is the development of a concept of IGRT dose quantification which allows a comparison of imaging dose with
commonly accepted variations of therapeutic dose.
Methods: It is assumed that dose variations of the treatment beam which are accepted in the spirit of the ALARA
convention can also be applied to the additional imaging dose. Therefore we propose three dose categories:
Category I: The imaging dose is lower than a 2 % variation of the therapy dose. Category II: The imaging dose is
larger than in category I, but lower than the therapy dose variations between different treatment techniques.
Category III: The imaging dose is larger than in Category II. For various treatment techniques dose measurements
are used to define the dose categories. The imaging devices were categorized according to the measured dose.
Results: Planar kV-kV imaging is a category I imaging procedure. kV-MV imaging is located at the edge between
category I and II and is for increasing fraction size safely a category I imaging technique. MV-MV imaging is for all
imaging technologies a category II procedure. MV fan beam CT for localization is a category I technology. Low
dose protocols for kV CBCT are located between category I and II and are for increasing fraction size a category I
imaging technique. All other investigated Pelvis-CBCT protocols are category II procedures. Fan beam CT scout
views are category I technology. Live imaging modalities are category III for conventional fractionation, but
category II for stereotactic treatments.
Conclusions: Dose from radiotherapy imaging can be categorized in terms of generally accepted dose variations
of therapy dose. This concept allows the quantification of daily dose from image guided radiotherapy in the spirit
of the ALARA convention.
Background
In radiation therapy the integral dose is increasing stead-
ily with the introduction of more imaging procedures to
the treatment process [1]. Image-guided radiotherapy
(IGRT) makes use of many different imaging techniques,
using modalities as portal imaging, fluoroscopy and CT
in many variations (fan-beam, cone-beam, MV, kV).
Clinically applied regimens are as simple as a single
setup image or as complex as intrafraction tumor track-
ing. The total imaging radiation dose experienced by a
patient can include multiple CT scans for planning,
pretreatment fluoroscopic studies to analyze tumor mo-
tion, and a series of interfraction and intrafraction im-
ages for target localization.
The quantification of the additional imaging dose in
terms of second cancer risk for the patient is not an
easy task. The report of the AAPM task group 75 [1]
on the management of imaging dose during image-
guided radiotherapy recommends to use the concept of
effective dose to determine the stochastic risk for the
patient. It is fundamentally important to compare the
imaging dose to the total dose delivered by the treat-
ment beams themself. The AAPM task group 75 [1]
discourages from naively equating imaging dose with
treatment beam, scatter, and leakage dose, since the
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comparison process is more complicated. As the dose-
response curve for radiation induced cancer might be
different at therapeutic dose levels when compared to
imaging doses, it is also not recommended to use ef-
fective dose to quantify therapy dose in order to com-
pare it to the effective dose from imaging. Therefore
the task group 75 [1] considers that it is not yet prac-
tical to quantitatively combine the evaluation of total
imaging dose with the evaluation of total therapeutic
dose. However, to manage imaging dose in the spirit of
the ALARA convention it is necessary to establish a
quantitative comparison between imaging and thera-
peutic dose.
The aim of this report is the development of a con-
cept which allows a comparison of imaging dose with
commonly accepted variations of the treatment beam,
scatter, and leakage dose. It is assumed that the dose
variations of the treatment beam which are accepted by
the radiation oncologist and/or medical physicist in the
spirit of the ALARA convention can also be applied to
the additional imaging dose.
Methods
Various measurements of peripheral imaging and treat-
ment dose have been published recently [2–6]. In this re-
port we focus for analysis on the measurements of Hälg et
al. [6] for the following reasons. Hälg et al. measured a
three-dimensional dose distribution in the Alderson phan-
tom with 183 TLDs. The radiotherapy treatment plans
which were irradiated were planned for an adolescent pa-
tient with a Rabdomyosarcoma in the prostate. Thus the
irradiated PTV was relatively small and as a consequence
the ratio of imaging to therapy dose large (the impact of
imaging is conservatively estimated). In addition not only
various radiotherapy treatment techniques, but also the
dose from treatment machines of several vendors was
measured. The measured imaging modalities, listed in
Table 1, included planar, CT and fluoroscopic imaging
with kV and MV beams, respectively. Details of the
measurements can be found in the publications of Hälg
et al. [6, 7].
The distribution of dose in the patient depends on sev-
eral factors. In planar imaging the dose to the patient is
greatest at the skin surface nearest to the source and
falls off progressively as the radiation transits the body
to the image detector. Axial imaging, which is the basis
for CT, differs in that the dose, by design, is distributed
nearly uniformly throughout the imaged volume to pro-
duce 3D images of uniform cross-sectional quality.
Therefore dose in planar imaging is concentrated at the
skin while dose for tomography is distributed more in
the manner of 3D radiation therapy [1]. A remaining
question is therefore how three-dimensional imaging
and therapy dose distributions can be evaluated. For this
reason the three-dimensional measurements were aver-
aged in cross-sectional slices with increasing distance
from the irradiated volume (PTV) in 2.5 cm steps (form
feet to head). The averaged dose was then compared to
the measured on-axis-dose in the superior-inferior direc-
tion reaching from the edge of the PTV to the head in
2.5 cm steps.
For the quantification of imaging dose in radiotherapy
we propose three categories:
(1)Category I: The imaging dose is lower than a 2 %
variation of the therapy dose.
(2)Category II: The imaging dose is larger as defined by
category I, but lower than the variation of therapy
dose between different treatment techniques.
(3)Category III: The imaging dose is larger than the
variation of therapy dose between different
treatment techniques which are clinically in use.
The reason for the definition of category I is the inter-
nationally accepted quality standard for radiotherapy
beam output variations of medical electron accelerators.
Many national protocols use 2 % as an upper limit for
output variations, which is, among others, defined based
on the ALARA principle [8–11]. Thus it is commonly
accepted that radiotherapy scatter and leakage can be
2 % higher than originally planned. We argue that an
additional imaging dose which is lower than the well ac-
cepted 2 % therapy dose variation does not need add-
itional justification.
In current clinical practice the choice of treatment
technique determines the amount of peripheral dose to
the patient. For example an IMRT treatment plan de-
livers more scatter and leakage dose than a conformal
3D plan. This additional dose is usually justified by a
better sparing of the organs at risk.
The ALARA principle is usually of low priority in the
choice of a treatment machine. However, the dose
Table 1 Analysed imaging devices and corresponding imaging
techniques used in this study. The machine parameters and
settings for each imaging modality can be found in [6]
Imaging device Imaging technique
Accuray cyberknife Stereoscopic kV planar images
Accuray tomotherapy MV fan beam CT
Elekta synergy MV portal images
Elekta XVI kV CBCT
GE HiSpeed DX/i CT scout views
Siemens oncor avant-garde MV CBCT and portal images
Varian clinac 21 iX MV portal images
Varian OBI kV CBCT and planar images
Varian truebeam kV CBCT
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variation originating from different treatment machines
while using the same treatment technique is even larger
than the variation with treatment technique (as will be
seen later). Therefore category II includes imaging modal-
ities which deliver a dose to the patient which is below the
dose variation originating from different treatment tech-
niques. This can provide a tool for justifying the additional
imaging dose if the benefit for the patient is similar to the
benefit from a modern treatment technique.
The treatment techniques, treatment machines and im-
aging technologies for which the three-dimensional dose
distribution was measured are listed in Table 1.
The magnitude of the therapeutic dose distribution is
proportional to the dose per fraction and thus the ratio
of imaging to therapeutic dose will depend on fraction
size. Therefore the categorization of imaging dose was
performed for 2, 5 and 10 Gy per fraction, respectively.
Results
In Fig. 1 the lines represent the measured central axis
therapy dose in mGy for a 2 Gy therapy fraction for a se-
lection of treatment techniques and machine manufac-
turers. The dose is plotted as a function of the distance
from the PTV. The corresponding symbols show the
average dose in the corresponding cross-sectional slice
in the phantom. Two things can be recognized. First, the
dose variation between different radiotherapy techniques
(Varian 3D conformal treatment and Varian IMRT) and
between different treatment machines using the same
technique (IMRT with Varian, Siemens and Tomotherapy)
are significant [7]. Second the central axis dose is in satis-
fying agreement with the average of the three-dimensional
dose distribution in each slice. Therefore we believe that
the central axis dose is a good measure of the deposited
energy per area from a therapeutic irradiation of a co-
planar treatment.
The same is shown in Fig. 2 for several imaging mo-
dalities. The conclusions from therapy can be applied
also to imaging. The central axis depth dose curve is
representative for the total deposited energy per slice
and large variations between the different imaging mo-
dalities can be observed.
In a next step the 2 % variation of the therapy dose
from a 3D conformal Varian treatment was calculated
from the measurements. The 3D conformal plan was
chosen, as it corresponds to the lowest scatter and leak-
age dose when compared to the other treatment options.
Thus it is a conservative estimate of the 2 % limit and
any other technique, as VMAT or IMRT would result in
a larger 2 % dose contribution. In Fig. 3 this 2 % dose
which defines the upper limit for category I is plotted as
the solid line as a function of the distance from the irra-
diated target volume on the central axis of the Alderson
phantom. For the category II limit the maximum dose
difference between Varian iX 3D-CRT, Varian iX IMRT,
Varian IX VMAT, Varian Truebeam FFF VMAT) was
determined and plotted as the dotted line. In addition
the dose difference between machines of different ven-
dors (Varian, Elekta, Siemens and Accuray Tomother-
apy) for the IMRT treatment technique is plotted as the
dashed line in the Fig. 3.
In Fig. 3a the dose contribution of planar imaging
is shown for kV and MV energies and different ven-
dors for a 2 Gy fraction size. In Fig. 3b different CT
imaging modalities are plotted including cone beam
and fan beam CT, low-and high dose CBCT and also
the CT dose from machines of different vendors. Fi-
nally Fig. 3c shows for 2 Gy fraction size the dose of
Fig. 1 Central axis therapy dose is plotted for a selection of
treatment techniques and manufacturers as a function of the
distance from the PTV as the solid lines for a 2 Gy fraction size.
The symbols represent the average dose in the corresponding
cross-sectional slice in the phantom
Fig. 2 Central axis imaging dose is plotted for a selection of imaging
modalities and manufacturers as a function of the distance from
the PTV as the solid lines for a 2 Gy fraction size. The symbols
represent the average dose in the corresponding cross-sectional
slice in the phantom
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a CT scout view which is sometimes used in proton
therapy for positioning purposes and the dose from
Cyberknife live imaging.
For a better comparison of the imaging modalities the
dose variation along the central axis was averaged. As
the additional cancer risk from imaging is supposed to
be a function of dose and volume the dose averaging
was performed in terms of median dose. The resulting
median doses are plotted in Fig. 4 for a 2 Gy fraction.
For each imaging modality or combination of images
two symbols were plotted representing the dose for one
or three applications per fraction, respectively.
The impact of daily imaging is decreasing with in-
creasing fraction size. Therefore the boundaries of the
dose categories are shifted to larger doses when moving
from conventional to hypofractionation. This can be
seen in Figs. 5 and 6 where the median imaging doses
are shown for a 5 Gy and a 10 Gy fraction, respectively.
Discussion
The classification of the different imaging techniques for
image guided radiotherapy is shown in Figs. 4, 5, and 6. It
can be concluded that planar kV-kV imaging is independ-
ent of fraction size always a category I imaging procedure.
kV-MV imaging is located at the edge between category I
and II and is for increasing fraction size safely a category I
imaging technique. MV-MV imaging, however, is for all
imaging technologies a category II procedure.
The dose optimized Tomotherapy MV fan beam CT
for localization is low in dose and a category I technol-
ogy. Low dose protocols for kV CBCT are located be-
tween category I and II and its classification may vary
according to fractionation. All other investigated Pelvis-
CBCT protocols are category II procedures.
Fan beam CT scout views which are sometimes used
for patient setup in proton therapy are category I. How-
ever, live imaging modalities must be viewed with care,
Fig. 3 Symbols represent the imaging dose as a function of the distance from the PTV for a 2 Gy fraction. The lines denote the borders
between the different dose categories. The category I/II and the category II/III-transition are represented by the solid and the dashed/dotted lines,
respectively. The solid line represents the 2 % dose variation of linac output, the dotted line the variation of treatment techniques and the
dashed line the variation between machine types. Planar imaging modalities are depicted in a), CT-imaging in b) and scout view and live
imaging in c)
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even when the fraction number is small and large dose
fractions are used. Although live imaging with 400 single
images is for a 10 Gy fractionation schedule in category
II, it should be noted that the dose up to around 20 cm
distance from the treated volume is more or less con-
stant (Fig. 3c) which is not reflected in the median dose.
This study has limitations that warrant consideration.
The dose measurements which were used in this study
were performed in an Alderson phantom for one indica-
tion. The therapeutic scatter and imaging dose varies
with PTV volume, PTV localisation and size of the pa-
tient. Therefore the IGRT dose presented in this study
cannot represent all clinical circumstances. In this work
a target in an adolescent patient with a relatively small
PTV was evaluated. The analysed imaging dose was
therefore large relative to the therapeutic dose and rep-
resents a conservative dose estimate.
It is important to note that radiation sensitivity varies
strongly with patient age. Children and adolescent pa-
tients are several times more sensitive than adults.
Therefore the dose categories presented in this work
should be used as an aid to apply the ALARA concept,
the imaging dose, however, should be managed on a
patient-by-patient basis.
In this work it was assumed that the size of the PTV is
independent of the used set-up procedure. However, the
application of different levels of image guidance allows
the reduction of the safety margins which define the size
of the PTV. As a consequence the integral dose of a
radiotherapy treatment using image guidance can be
smaller than that without image guidance. This may
somehow compensate for the additional imaging dose.
Unfortunately such effects cannot be quantified until we
have a new concept for combining therapy and imaging
dose into a risk equivalent quantity.
Conclusions
In this work a concept was developed to quantify daily
dose from image guided radiotherapy in the spirit of the
ALARA convention. Three dose categories are proposed:
category I which is defined by a dose contribution
smaller than a 2 % variation of the therapeutic dose,
Fig. 5 Classification of various imaging modalities according to
median dose in dose categories for a therapeutic dose of 2 Gy
per fraction. Two symbols per imaging modality are plotted representing
the increase of dose when imaging is applied three times per
fraction instead of one
Fig. 6 Classification of various imaging modalities according to
median dose in dose categories for a therapeutic dose of 10 Gy
per fraction. Two symbols per imaging modality are plotted representing
the increase of dose when imaging is applied three times
per fraction instead of one
Fig. 4 Classification of various imaging modalities according to
median dose in dose categories for a therapeutic dose of 2 Gy
per fraction. Two symbols per imaging modality are plotted representing
the increase of dose when imaging is applied three times per
fraction instead of one
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category II which is defined by the dose variation between
different treatment techniques and category III which ex-
ceeds the dose level of category II. It is proposed that
IGRT dose contributions which fall into category I do
not need additional justification. If the imaging dose
is in category II the additional imaging dose is justi-
fied if the benefit for the patient is similar to the benefit
from the application of a modern treatment technique.
Imaging procedures which fall into category III need
additional justification.
It can be concluded that none of the investigated im-
aging procedures, except the live imaging, falls into cat-
egory III. Most imaging methods, including the Pelvis
CBCT protocols and MV-MV planar imaging are cat-
egory II and will add a similar amount of extra dose to
the patient than an IMRT treatment when compared to
3D conformal radiotherapy. Optimized low dose CBCT,
MV fan beam CT (of Tomotherapy) and kV-kV planar
imaging are category I modalities which, in our opinion,
do not need additional justification.
Competing interests
All authors read and approved the final manuscript.
Authors’ contributions
US designed the study and wrote the manuscript. JB developed the idea of
risk quantification. RH performed the measurements. All authors reviewed
and approved the final manuscript.
Acknowledgements
This study was supported financially in part by the KIRO grant from the
Federal Office of Public Health (FOPH), Switzerland.
Received: 28 April 2015 Accepted: 24 August 2015
References
1. Murphy MJ, Balter J, Balter S, BenComo JA Jr, Das IJ, Jiang SB, et al. The
management of imaging dose during image-guided radiotherapy: report of
the AAPM Task Group 75. Med Phys. 2007;34(10):4041–63.
2. Walter C, Boda-Heggemann J, Wertz H. Phantom and in-vivo measurements of
dose exposure by image-guided radiotherapy (IGRT): MV portal images vs. kV
portal images vs. cone-beam CT. Radiother Oncol. 2007;85(3):418–23.
3. Ding GX, Duggan DM, Coffey CW. Accurate patient dosimetry of kilovoltage
cone-beam CT in radiation therapy. Med Phys. 2008;35:1135–44.
4. Ding GX, Coffey CW. Radiation dose from kilovoltage cone beam computed
tomography in an image-guided radiotherapy procedure. Int J Radiat Oncol
Biol Phys. 2009;73:610–7.
5. Stock M, Palm A, Altendorfer A, Steiner E, Georg D. IGRT induced dose
burden for a variety of imaging protocols at two different anatomical sites.
Radiother Oncol. 2012;102:355–63.
6. Halg RA, Besserer J, Schneider U. Systematic measurements of whole-body
imaging dose distributions in image-guided radiation therapy. Med Phys.
2012;39(12):7650–61.
7. Halg RA, Besserer J, Schneider U. Systematic measurements of whole-body
dose distributions for various treatment machines and delivery techniques
in radiation therapy. Med Phys. 2012;39(12):7662–76.
8. Klein EE, Hanley J, Bayouth J, Yin FF, Simon W, Dresser S, et al. Task Group
142 report: quality assurance of medical accelerators. Med Phys.
2009;36(9):4197–212.
9. Frauchiger D, Besserer J, Bulling S, Corradini N, Hasenbalg F, Henrich L, et al.
Quality control of medical electron accelerators, Recommendations Number 11
of the SGSMP. 2014. 3 908 125 57 X.
10. Meijer GJ, van Kleffens HJ, Mijnheer BJ, Quality control of medical linear
accelerators: Current practice and minimum requirements, Netherlands
commission on radiation dosimetry. 1996. Report 9.
11. Mayles WPM, Lake R, McKenzie A, Macaulay EM, Morgan HM, Jordan TJ,
et al. Physics aspects of quality control in radiotherapy, IPEM report.
New York: IPEM; 1999. p. 81
.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schneider et al. Radiation Oncology  (2015) 10:188 Page 6 of 6
